Recombinant
RabMAb

Recombinant Anti-CD86 antibody [EP1158Y] - Low endotoxin, Azide free (ab209896)

Rabbit recombinant monoclonal CD86 antibody [EP1158Y]. Validated in WB, IP, ELISA, IHC, ICC/IF and tested in Human, Cynomolgus monkey. Cited in 8 publication(s).

Overview

  • Product name

    Anti-CD86 antibody [EP1158Y] - Low endotoxin, Azide free
    See all CD86 primary antibodies
  • Description

    Rabbit monoclonal [EP1158Y] to CD86 - Low endotoxin, Azide free
  • Host species

    Rabbit
  • Tested applications

    Suitable for: IHC-P, IHC-Fr, WB, ICC/IF, ELISA, IPmore details
  • Species reactivity

    Reacts with: Human, Cynomolgus monkey
  • Immunogen

    Synthetic peptide within Human CD86 aa 1-100 (N terminal). The exact sequence is proprietary.

  • Positive control

    • Raji cell membrane lysate Human tonsil tissue
  • General notes

    ab209896 is a carrier-free antibody designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab209896 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.
IHC-Fr Use at an assay dependent concentration. PubMed: 21998115
WB Use at an assay dependent concentration. Detects a band of approximately 70 kDa.

Please check the parent abID, ab53004, for more information on dilutions.

ICC/IF Use at an assay dependent concentration.
ELISA Use at an assay dependent concentration.
IP Use at an assay dependent concentration.

Target

  • Function

    Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.
  • Tissue specificity

    Expressed by activated B-lymphocytes and monocytes.
  • Sequence similarities

    Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
    Contains 1 Ig-like V-type (immunoglobulin-like) domain.
  • Post-translational
    modifications

    Polyubiquitinated; which is promoted by MARCH8 and results in endocytosis and lysosomal degradation.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • Activation B7-2 antigen 3 antibody
    • Activation B7-2 antigen antibody
    • B-lymphocyte activation antigen B7-2 2 antibody
    • B-lymphocyte activation antigen B7-2 antibody
    • B7 2 antibody
    • B7 antibody
    • B7-2 antibody
    • B7.2 antibody
    • B70 antibody
    • B72 antibody
    • B72 antigen antibody
    • BU63 antibody
    • CD28 antigen ligand 2 2 antibody
    • CD28 antigen ligand 2 antibody
    • Cd28l2 antibody
    • CD28LG2 antibody
    • CD86 antibody
    • CD86 antigen (CD28 antigen ligand 2 B7 2 antigen) antibody
    • CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 1, 2 antibody
    • CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) antibody
    • CD86 antigen antibody
    • CD86 molecule antibody
    • CD86_HUMAN antibody
    • CLS1 antibody
    • CTLA-4 counter-receptor B7.2 2 antibody
    • CTLA-4 counter-receptor B7.2 2, 3 antibody
    • CTLA-4 counter-receptor B7.2 antibody
    • Early T-cell costimulatory molecule 1 antibody
    • ETC-1 antibody
    • FUN 1 antibody
    • FUN-1 antibody
    • FUN1 antibody
    • LAB72 antibody
    • Ly-58 antibody
    • Ly58 antibody
    • MB7 antibody
    • MB7-2 antibody
    • Membrane glycoprotein antibody
    • MGC34413 antibody
    • T lymphocyte activation antigen CD86 precursor antibody
    • T-lymphocyte activation antigen CD86 antibody
    • TS/A-2 antibody
    see all

Images

  • Pattern of macrophage infiltration in colorectal cancer and healthy surrounding tissues.

    The immunoreactivity to CD86 (M1-MF marker, C–D) was analyzed in colorectal cancer (Panel D) and healthy surrounding mucosa (Panel C) using ab53004.

    Serial sections (4 µm) of samples containing tumor and normal mucosa from each patient were stained. Endogenous peroxidase activity was suppressed by immersion in 0.3% hydrogen peroxide. Once blocked with 5% horse serum, sections were incubated overnight (4°C) with the primary antibody. A horse anti-mouse/rabbit biotinylated antibody 1:200 was used as a secondary antibody. The ABC system followed by the DAB were used for development. All tissues were counterstained with hematoxylin.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab53004).

  • Primary antibody, ab53004 was used at concentrations between 0.1 - 1000 ng/ml. An Alkaline Phosphatase Goat Anti-Rabbit IgG (H+L) was used as the secondary antibody at 1:2500 dilution. Antigen concentration was 100ng/ml. 

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab53004).

  • Immunocytochemistry/Immunofluorescence analysis of Raji (Human Burkitt's lymphoma cell line) labelling CD86 with purified ab53004 at 1/500.

    Cells were fixed with 4% PFA and permeabilized with 0.1% triton X-100. ab150077 Goat anti rabbit IgG (Alexa Fluor® 488) at 1/1000 was used as the secondary antibody. Nuclei were counterstained with DAPI.

    PBS was used instead of the primary antibody as the negative control.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab53004).

  • ab53004, at a 1/100 dilution, staining human CD86 in tonsil tissue, using Immunohistochemistry, paraffin embedded tissue.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab53004).

  • This IHC data was generated using the same anti-CD86 antibody clone, EP1158Y, in a different buffer formulation (cat# ab53004).

    ab53004 staining CD86 in Cynomolgus Monkey lymph node tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 10% serum for 20 minutes at room temperature; antigen retrieval was by heat mediation in a citrate buffer, pH 6.0. Samples were incubated with primary antibody (1/800) for 30 minutes at room temperature. An undiluted Biotin-conjugated Goat anti-rabbit IgG polyclonal was used as the secondary antibody.

  • This ICC/IF data was generated using the same anti-CD86 antibody clone, EP1158Y, in a different buffer formulation (cat# ab53004).

    Immunocytochemistry/Immunofluorescence analysis of Raji (Human Burkitt's lymphoma cell line) labelling CD86 with purified ab53004 at 1/500. Cells were fixed with 4% PFA and permeabilized with 0.1% triton X-100. ab150077 Goat anti rabbit IgG (Alexa Fluor® 488) at 1/1000 was used as the secondary antibody. Nuclei were counterstained with DAPI. PBS was used instead of the primary antibody as the negative control.

  • Anti-CD86 antibody [EP1158Y] - Low endotoxin, Azide free (ab209896) + Raji (human Burkitt's lymphoma) whole cell lysate at 15 µg

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) (ab97051)

    Observed band size: 70 kDa
    why is the actual band size different from the predicted?


    Exposure time: 10 seconds


    Blocking buffer and concentration: 5% NFDM/TBST

    Diluting buffer and concentration: 5% NFDM/TBST

References

This product has been referenced in:

  • Jiang T  et al. Physical Exercise Improves Cognitive Function Together with Microglia Phenotype Modulation and Remyelination in Chronic Cerebral Hypoperfusion. Front Cell Neurosci 11:404 (2017). Read more (PubMed: 29311834) »
  • Bargerstock E  et al. Is peripheral immunity regulated by blood-brain barrier permeability changes? PLoS One 9:e101477 (2014). Read more (PubMed: 24988410) »
See all 8 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab209896.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up